<DOC>
	<DOC>NCT01164007</DOC>
	<brief_summary>This study will assess the preliminary antitumor activity and safety profile of a combination of Avastin and dacarbazine in patients with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease. Patients will receive Avastin 10mg/kg iv every 2 weeks and dacarbazine 800mg/m2 every 4 weeks. The anticipated time on study treatment is until disease progression.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; cutaneous malignant melanoma; clinical evidence of metastatic disease and/or unresectable regional lymphatic disease and/or extensive in transit recurrent disease; measurable lesions. prior interferon alfa and/or cytokine therapy for metastatic disease; prior chemotherapy for metastatic disease; brain metastases; chronic daily treatment with high dose aspirin (&gt;325mg/day); other coexisting malignancies, or malignancies diagnosed within the past 5 years, other then basal cell cancer or cervical cancer in situ.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>